This study is a first-in-human, randomized, placebo-controlled, 4-Part, single ascending dose (SAD) and multiple ascending dose (MAD) study in healthy adult subjects and adult subjects with Classic Galactosemia.
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Number of Participants With Treatment-emergent Adverse Events
Timeframe: Events after 1 day of administration.
Number of Participants With Treatment-emergent Adverse Events
Timeframe: 7 Days after Dosing
Number of Participants With Treatment-emergent Adverse Events
Timeframe: 28 Days of Dosing
Number of Participants With Treatment-emergent Adverse Events
Timeframe: 90 Days after Dosing